PPARγ 激动剂作为脑疟疾辅助治疗的应用。
The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria.
机构信息
Sandra A. Rotman Laboratories, McLaughlin-Rotman Centre for Global Health, Toronto General Hospital, University Health Network, 101 College Street, Suite 10-359, Toronto, ON, Canada M5G 1L7.
出版信息
PPAR Res. 2012;2012:513865. doi: 10.1155/2012/513865. Epub 2011 Jun 9.
Abstract
Cerebral malaria is a severe complication of Plasmodium falciparum infection associated with high mortality even when highly effective antiparasitic therapy is used. Adjunctive therapies that modify the pathophysiological processes caused by malaria are a possible way to improve outcome. This review focuses on the utility of PPARγ agonists as an adjunctive therapy for the treatment of cerebral malaria. The current knowledge of PPARγ agonist use in malaria is summarized. Findings from experimental CNS injury and disease models that demonstrate the potential for PPARγ agonists as an adjunctive therapy for cerebral malaria are also discussed.
摘要
脑型疟疾是恶性疟原虫感染的严重并发症，即使采用高效抗疟治疗，死亡率仍很高。辅助治疗可以改变疟疾引起的病理生理过程，从而改善预后。本文重点关注过氧化物酶体增殖物激活受体γ激动剂作为治疗脑型疟疾的辅助治疗的应用。本文总结了过氧化物酶体增殖物激活受体γ激动剂在疟疾中的应用。还讨论了实验性中枢神经系统损伤和疾病模型中的发现，这些发现表明过氧化物酶体增殖物激活受体γ激动剂作为脑型疟疾辅助治疗的潜力。
相似文献
1
The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria.PPARγ 激动剂作为脑疟疾辅助治疗的应用。
PPAR Res. 2012;2012:513865. doi: 10.1155/2012/513865. Epub 2011 Jun 9.
2
PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria.过氧化物酶体增殖物激活受体γ（PPARγ）激动剂可改善实验性脑型疟疾的存活率和神经认知结果，并在人类疟疾中诱导神经保护途径。
PLoS Pathog. 2014 Mar 6;10(3):e1003980. doi: 10.1371/journal.ppat.1003980. eCollection 2014 Mar.
3
Inhibiting the Mammalian target of rapamycin blocks the development of experimental cerebral malaria.抑制雷帕霉素的哺乳动物靶点可阻止实验性脑型疟疾的发展。
mBio. 2015 Jun 2;6(3):e00725. doi: 10.1128/mBio.00725-15.
4
Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria.脑型疟疾和其他严重的恶性疟原虫疟疾的辅助治疗。
Expert Rev Anti Infect Ther. 2010 Sep;8(9):997-1008. doi: 10.1586/eri.10.90.
5
Do we know enough to find an adjunctive therapy for cerebral malaria in African children?我们是否掌握了足够的知识来找到针对非洲儿童脑型疟疾的辅助治疗方法？
F1000Res. 2017 Nov 22;6:2039. doi: 10.12688/f1000research.12401.1. eCollection 2017.
6
Cerebral Malaria: Current Clinical and Immunological Aspects.脑型疟疾：当前临床与免疫学方面
Front Immunol. 2022 Apr 20;13:863568. doi: 10.3389/fimmu.2022.863568. eCollection 2022.
7
Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria.罗格列酮可调节对恶性疟原虫感染的天然免疫反应，并改善实验性脑型疟疾的预后。
J Infect Dis. 2009 May 15;199(10):1536-45. doi: 10.1086/598222.
8
Adjunctive therapy for severe malaria: a review and critical appraisal.重症疟疾的辅助治疗：综述与评价。
Malar J. 2018 Jan 24;17(1):47. doi: 10.1186/s12936-018-2195-7.
9
Modulation of cerebral malaria by curcumin as an adjunctive therapy.姜黄素作为辅助治疗对脑型疟疾的调节作用。
Braz J Infect Dis. 2013 Sep-Oct;17(5):579-91. doi: 10.1016/j.bjid.2013.03.004. Epub 2013 Jul 29.
10
Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial.过氧化物酶体增殖物激活受体γ激动剂作为恶性疟原虫疟疾辅助治疗的应用：一项随机、双盲、安慰剂对照试验。
Clin Infect Dis. 2009 Sep 15;49(6):841-9. doi: 10.1086/605431.
引用本文的文献
1
Pathophysiological Mechanisms in Gaseous Therapies for Severe Malaria.重症疟疾气体疗法的病理生理机制
Infect Immun. 2016 Mar 24;84(4):874-882. doi: 10.1128/IAI.01404-15. Print 2016 Apr.
2
Pathway-GPS and SIGORA: identifying relevant pathways based on the over-representation of their gene-pair signatures.Pathway-GPS 和 SIGORA：基于基因对特征的过表达来识别相关途径。
PeerJ. 2013 Dec 19;1:e229. doi: 10.7717/peerj.229.
3
Lipoxin A₄ and 15-epi-lipoxin A₄ protect against experimental cerebral malaria by inhibiting IL-12/IFN-γ in the brain.脂氧素 A4 和 15-表脂氧素 A4 通过抑制大脑中的 IL-12/IFN-γ 来保护实验性脑型疟疾。
PLoS One. 2013 Apr 16;8(4):e61882. doi: 10.1371/journal.pone.0061882. Print 2013.
本文引用的文献
1
Therapeutic Potential of PPARγ Activation in Stroke.过氧化物酶体增殖物激活受体γ 在脑卒中的治疗潜能。
PPAR Res. 2008;2008:461981. doi: 10.1155/2008/461981. Epub 2008 Apr 13.
2
Endothelium-based biomarkers are associated with cerebral malaria in Malawian children: a retrospective case-control study.内皮细胞标志物与马拉维儿童脑型疟疾相关：一项回顾性病例对照研究。
PLoS One. 2010 Dec 29;5(12):e15291. doi: 10.1371/journal.pone.0015291.
3
Artemisinin resistance--the clock is ticking.青蒿素耐药性——时间紧迫。
Lancet. 2010 Dec 18;376(9758):2051-2. doi: 10.1016/S0140-6736(10)61963-0.
4
Increased levels of glutamate in the central nervous system are associated with behavioral symptoms in experimental malaria.中枢神经系统中谷氨酸水平的升高与实验性疟疾中的行为症状有关。
Braz J Med Biol Res. 2010 Dec;43(12):1173-7. doi: 10.1590/s0100-879x2010007500130. Epub 2010 Nov 19.
5
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.青蒿琥酯与奎宁治疗非洲儿童重症恶性疟的疗效比较（AQUAMAT）：一项开放标签、随机临床试验。
Lancet. 2010 Nov 13;376(9753):1647-57. doi: 10.1016/S0140-6736(10)61924-1. Epub 2010 Nov 7.
6
Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia.微透析结合血液取样技术用于测定脑缺血沙土鼠脑和血液中的罗格列酮和葡萄糖。
J Pharm Biomed Anal. 2011 Mar 25;54(4):759-64. doi: 10.1016/j.jpba.2010.10.008. Epub 2010 Oct 16.
7
Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria.脑型疟疾和其他严重的恶性疟原虫疟疾的辅助治疗。
Expert Rev Anti Infect Ther. 2010 Sep;8(9):997-1008. doi: 10.1586/eri.10.90.
8
The roles of TNF in brain dysfunction and disease.TNF 在脑功能障碍和疾病中的作用。
Pharmacol Ther. 2010 Dec;128(3):519-48. doi: 10.1016/j.pharmthera.2010.08.007. Epub 2010 Sep 8.
9
Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia.替米沙坦，过氧化物酶体增殖物激活受体 γ 的部分激动剂，可改善反复脑缺血大鼠空间记忆损伤和海马细胞凋亡。
Brain Res. 2010 Sep 24;1353:125-32. doi: 10.1016/j.brainres.2010.07.017. Epub 2010 Jul 14.
10
Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism.过氧化物酶体增殖物激活受体 γ（PPARγ）通过非基因组机制调节内皮细胞炎症反应是必需的。
Eur J Cell Biol. 2010 Sep;89(9):645-53. doi: 10.1016/j.ejcb.2010.04.002. Epub 2010 May 26.
Zotero 插件